News Release

Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical

Trial for their investigational compound SUVN-G3031
HYDERABAD, INDIA (April 13, 2015) - Suven Life Sciences Ltd (Suven) today announced that it
has completed the single ascending dose (SAD) studies of SUVN-G3031 in healthy human
volunteers and initiated multiple ascending dose studies (MAD) as a part of the Phase I study
currently ongoing in USA under US-IND 123179. SUVN-G3031 is a potent, selective, brain
penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of
cognitive dysfunction associated with Alzheimers disease and Schizophrenia.
The Phase-1 study was designed to evaluate the safety, tolerability and pharmacokinetics of
SUVN-G3031 in healthy volunteers. The tolerability of SUVN-G3031 up to the highest dose
administered in SAD study is excellent. No serious adverse events occurred. SUVN-G3031
demonstrated excellent pharmacokinetics with a potential for once in a day dosing.
Histaminergic dysfunction has been strongly associated with the cognitive and behavioral
deficits observed in several CNS disorders. Hence novel, potent, selective, brain penetrant and
orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new
line of treatment for the unmet medical needs in Alzheimers disease, Schizophrenia and other
CNS disorders.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and
commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. The Company has eleven (11) internally-discovered
therapeutic drug candidates currently in pre-clinical stage of development targeting conditions
such as ADHD, dementia, depression, Huntingtons disease, Parkinsons disease and obesity in
addition to Phase 2 ready developmental candidate SUVN-502 for and Phase1 candidate SUVNG3031 for Alzheimers disease and Schizophrenia.
For more information please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued success in growth of sales that may
make our products/services offerings less competitive; Suven may not undertake to update any forwardlooking statements that may be made from time to time.

Suven Life Sciences Limited

C IN : L 2 41 1 0TG 1 98 9P L C 00 9 71 3
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I
Road No.5 I Avenue 7 I Banjara Hills I Hyderabad 500 034 I Telangana I India
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com